Systemic treatment for coexisting mucinous urethral adenocarcinoma and prostate adenocarcinoma

IJU Case Reports

article

Kunihisa Nezu¹  Teppei Okubo¹  Manabu Shiraiwa²  Yoshihiro Nozawa³  Atsushi Kyan¹ 

[1] Department of Urology, Shirakawa Kousei General Hospital;Department of Urology, Shirakawajinhinyokinaika Clinics;Department of Pathology, Shirakawa Kousei General Hospital

关键词: adenocarcinoma;    carcinosarcoma;    epithelial-mesenchymal transition;    prostate;    urethral neoplasms.;   

DOI  :  10.1002/iju5.12210

学科分类：社会科学、人文和艺术（综合）

来源: Wiley

【 摘 要 】

Introduction Mucinous urethral adenocarcinoma is a rare and progressive cancer of the prostatic urethra. Reports on palliative systemic treatment for mucinous urethral adenocarcinoma are few. We present a case of coexisting mucinous urethral and prostate adenocarcinomas managed with systemic treatment. Case presentation A 66-year-old man presented with gross hematuria and urinary retention. Prostate-specific antigen level was elevated, at 99 ng/mL, and prostate biopsy revealed moderately to poorly differentiated adenocarcinoma. Hormone therapy and standard chemotherapy for prostate adenocarcinoma were ineffective. Prostate re-biopsy revealed coexisting mucinous urethral and prostate adenocarcinomas. Gemcitabine + cisplatin chemotherapy and folinic acid + 5-fluorouracil + irinotecan chemotherapy temporarily suppressed the cancer, but 14 months after presentation, he developed liver metastasis and died. Autopsy revealed metastasis of both mucinous urethral adenocarcinoma and carcinosarcoma. Conclusion Mucinous urethral adenocarcinoma is difficult to diagnose in coexistence with prostate adenocarcinoma. This was an extremely rare case showing chemoresistance due to epithelial-mesenchymal transition.

【 授权许可】

CC BY|CC BY-NC|CC BY-NC-ND